以溶血素为抗原的新型肺炎球菌疫苗的研究进展

Progress in research on novel Streptococcus pneumoniae vaccines using pneumolysin as antigen

肺炎球菌是人类最常见的细菌性病原微生物之一,是引起肺炎、脑膜炎、中耳炎、鼻窦炎和菌血症等的主要病原体。肺炎球菌感染在全球范围内导致较高的发病率和死亡率,且在诊断、治疗和预防方面存在许多挑战。针对肺炎球菌相关疾病,目前已上市的肺炎球菌多糖疫苗存在制备成本高、血清型覆盖率有限、血清型替代等局限性,因此,急需开发广谱的新型肺炎球菌疫苗。其中溶血素作为潜在的候选蛋白抗原,在新型肺炎球菌疫苗开发中受到广泛关注。本文对以溶血素为抗原蛋白的新型肺炎球菌疫苗的研究进展作一综述。

Streptococcus pneumoniae is one of the most common bacterial pathogens,which is the main cause of pneumonia,meningitis,otitis media,sinusitis and bacteremia. Pneumococcal infection has caused a high incidence rate and mortality worldwide,which faces many challenges in diagnosis,treatment and prevention. Polysaccharide vaccines targeting S. pneumoniae-related diseases have some limitations,such as high preparation cost,limited serotype coverage,and serotype replacement. Therefore,it is urgent to develop novel broad-spectrum S. pneumoniae vaccines. As a potential candidate protein antigen,pneumolysin has been widely used in the development of novel S. pneumoniae vaccines. This paper reviews the progress in research on novel S. pneumoniae vaccines using pneumolysin as antigen protein.